There have been significant updates to several sections of the SPC, including the following:

Change to section 4.2 - Posology and method of administration

EXJADE is not recommended in patients with severe hepatic impairment (Child-Pugh Class C). In patients with moderate hepatic impairment (Child-Pugh Class B), the dose should be considerably reduced followed by progressive increase up to a limit of 50% (see sections 4.4 and 5.2), and EXJADE must be used with caution in such patients. Hepatic function in all patients should be monitored before treatment; every 2 weeks during the first month and then every month (see section 4.4).

Change to section 4.4 - Special warnings and precautions for Use

EXJADE is not recommended in patients with severe hepatic impairment (Child-Pugh Class C) (see section 5.2).

Please refer to SPC link below for full information on all changes.